Recently, monomeric compounds extracted from traditional Chinese herbal medicines for the treatment of cardiovascular diseases have attracted substantial attention due to their high efficiency and safety (Xu and Yang, 2009). Sophora alopecuroides L., a perennial shrub, harbors several active components such as quinolizidine alkaloids, flavonoids, and flavone stilbenes. These compounds have shown efficacy in treating acute dysentery and ameliorating specific cardiovascular conditions (Li Y. et al., 2020; Wang et al., 2020; Zhou et al., 2020). Among these compounds, aloperine (ALO), a quinolizidine alkaloid, has gained attention from researchers worldwide (Wang et al., 2015; Lv et al., 2020; Ye et al., 2020). Studies have revealed ALO’s potential in enhancing cardiac function, particularly in conditions such as ischemia-reperfusion and coronary artery microembolization (Mao et al., 2019). Moreover, ALO can reduce lipid peroxidation and ventricular remodeling in rats with atherosclerosis-induced myocardial hypertrophy (Li W. et al., 2020).

Evidence suggests that ion channels of cardiac myocytes are key to understanding the mechanisms of cardiac dysfunction and arrhythmia (Thiel et al., 1997). Previous research has demonstrated antiarrhythmic effect of ALO by inhibiting voltage-gated sodium currents in rat ventricular myocytes in a concentration-dependent manner (Li et al., 2021). Voltage-dependent potassium (Kv) channels play crucial role in repolarizing cell membranes and modulating membrane excitability, with various subtypes in the heart that are associated with diseases (MacKinnon, 1995). Among these, Kv4.2 (encoded by KCND2) and Kv4.3 (encoded by KCND3) act as pore-forming subunits responsible for generating the transient outward K+ current (Ito) (Drum et al., 2016; Zhang et al., 2021). Ito constitutes a six transmembrane segmented (S1–S6) ion channel involved in mediating the transient outward K+ current. In general, variations in its current amplitude and dynamic characteristics may affect several normal physiological functions of the heart, such as the contractile function and impulse conduction process to potentially cause arrhythmias (Workman et al., 2001). Amiodarone, a commonly prescribed medication for arrhythmia, exerts its effects by inhibiting potassium channels, which results in prolonging the third phase of the action potential in the heart’s conduction system cells (Zimetbaum, 2007; Lei et al., 2018).

Multiple mechanisms have been hypothesized to contribute to AF development via structural and electrical remodeling of the atrial tissue. Several factors, including multiple wavelets and increased focal autoregulation in the atria, have been intensively investigated, and their importance during this process has been confirmed (Sagris et al., 2021). Variations in the electrical remodeling of cardiac ion channels are associated with AF. Early and delayed afterdepolarizations may underlie the ectopic activity that triggers AF (Brundel et al., 2022). Since the phase 0 depolarization generated by the fast sodium channel is rapid and of short duration, it has minimal impact on the tricuspid effective refractory period (ERP). Therefore, the shortening of the ERP occurs primarily during the repolarization phase, particularly in phases 2 and 3. The physiological structures within the atrium, including the pulmonary vein muscle cuffs, valves, superior and inferior vena cava inlets, and coronary sinuses, could all be the anatomical basis for fold formation.

Manville et al. demonstrated that ALO relaxes blood vessels by activating the Kv7.5 vascular-expressed potassium channel (Manville et al., 2019). However, the effect of ALO on cardiac Kv channels remains unclear. Kv4 channels represent the primary subtypes of transient outward currents, characterized by rapid activation and inactivation. They play a crucial role in shaping the morphology of myocardial action potential (AP).

In this study, we investigated the impact of ALO on Ito in rat atrial myocytes in vitro and assessed its influence on acetylcholine-induced arrhythmias in vivo. Molecular docking was performed to validate ligand-protein binding interactions. This provides a preliminary theoretical and practical basis for the further development and utilization of this drug and its analog compounds.

Isolation of single atrial myocytes from SD rat hearts was performed as previously described (Guinamard et al., 2014). Briefly, the animals were heparinized (2000 IU/kg, i.p.) for 10 min and then anesthetized with 2% sodium pentobarbital solution (40 mg/kg, i.p.). Following successful anesthesia, the animals were placed in the supine position to open the chest. The heart was cut and then cleaned in Ca2+-free Tyrode’s solution containing the following compounds (in mM): HEPES 5.0, glucose 10.0, NaH2PO4 0.33, MgCl2 1.0, KCl 5.4, and NaCl 135 (pH adjusted to 7.3 with NaOH). Excess tissue was trimmed to ligate the aorta into the Langendorff perfusion device. The calcium-saturated Tyrode’s solution was obtained by adding CaCl2 (1.8 mM) to the Ca2+-free Tyrode’s solution to resuscitate the cardiac tissue for 30 s and to remove the remaining blood. Residual blood from the heart was washed away after 5 min of continuous perfusion with Ca2+-free Tyrode’s solution. The hearts were then digested with Ca2+-free Tyrode’s solution containing taurine (0.4 g/L), BSA (1 g/L), and type II collagenase (0.4 g/L) for 20 min until the heart became enlarged and soft, and the effluent became viscous and turbid. Temperature was maintained at 37°C during perfusion with 95% O2 and 5% CO2. The atrial tissue was cut and filtered using a 100-mesh filter to obtain individual atrial myocytes, and the cell suspension was washed three times with Krebs solution containing (in mM): EGTA 1.0, KCl 25.0, KOH 89.0, glucose 11.0, taurine 10.0, L-glutamic acid 70.0, NaH2PO4 10.0, and HEPES 5.0 (pH adjusted to 7.4 with KOH) for 10 min to discard the supernatant. The cells were maintained at room temperature (23°C ± 2°C) for 30 min in the dark and then stored in Krebs solution at 4°C.

The crystal structures of KCND2 (PDB ID: 1NN7 Chain A), KCND3 (PDB ID: 2I2R Chain A), and KCNIP4 (predicted protein crystal structure generated by AlphaFold2) were acquired from the RCSB PDB database or AlphaFold2. The acquired protein crystals were processed using the Protein Preparation Wizard module in Schrödinger software. The 2D sdf structure files of ALO and amiodarone obtained from the PubChem database (https://pubchem.ncbi.nlm.nih.gov/) were processed using the LigPrep module in the Schrödinger software to generate their respective 3D chiral conformations. The SiteMap module in the Schrödinger software was employed to predict the optimal binding sites between the ligand and protein. Thereafter, the Receptor Grid Generation module in the Schrödinger software was used to set the most appropriate enclosing box to wrap the predicted binding sites perfectly, and the active sites of the three proteins were obtained on this basis. Molecular docking (with the highest precision, XP docking) was performed on the two ligand compounds and the active sites of three proteins. The interaction of the ligand and the active sites of the protein was analyzed through the MM-GBSA calculation. MM-GBSA dG Bind can approximately represent the binding free energy between ligands and proteins.

To examine the impact of ALO on peak Ito, a single square-wave stimulus of 70 mV for 300 ms at a holding potential of −80 mV was administered in the voltage clamp mode to elicit an outward current. As presented in Figure 1A, the current was almost completely suppressed by 2 μM 4-aminopyridine (4-AP), an Ito-specific blocker, and it was partially restored by removing 4-AP. The current induced in this stimulation mode was Ito. Subsequently, 10 μM ALO was perfused to inhibit Ito; however, the inhibitory effect was not as significant as that of 4-AP. Ito induced by ALO at various concentrations is depicted in Figure 1B. We noted that 1 μM ALO elicited no significant alterations compared to the control group, whereas treatments with 3 and 10 μM ALO resulted in a reduction relative to the control group. This observation suggests that 3 and 10 μM ALO can inhibit transient outward potassium channels. Moreover, the current density was slightly higher than that of the control group when the concentration was >30 μM. An increase in Ito is the mechanism that causes Brugada syndrome and early repolarization syndrome. Nevertheless, excessive inhibition or an increase in Ito may induce abnormal changes in the channel, ultimately resulting in cardiovascular disease. ALO at 3 and 10 μM moderately affected Ito and alleviated the abnormal function and expression of Ito in the diseased hearts. Therefore, 3 and 10 μM ALO were used for subsequent experiments. As presented in Table 1, the peak current is displayed as the current density (pA/pF). At 70 mV depolarization voltage, the concentration of ALO at 1, 3, and 10 μM suppressed Ito and reduced the current by 3.03% ± 3.65%, 16.92% ± 5.16%, and 30.09% ± 6.13% (p < 0.01), respectively.

Figure 1. Effect of ALO on Ito in atrial myocytes (data from double determinations in n = 3 rats, representing a total of n = 6 measurements). (A) Effect of ALO on the original current for the single stimulus diagram of Ito. (B) The effects of different concentrations of ALO on Ito. *p < 0.05, **p < 0.01 versus the control.

Table 1. Peak current density measured at 70 mV for various concentrations of ALO.

To investigate the impact of ALO on Ito across various voltage conditions, we maintained the potential at −80 mV in the voltage clamp mode. We applied a square wave ranging from −50–70 mV in 10 mV increments for 500 ms at 0.5 Hz to elicit Ito response before and after ALO administration. As presented in Figures 2A, 3 and 10 μM ALO treatments reduced the current compared to the control group. Figure 2B indicates that 3 and 10 μM ALO treatments significantly shifted the I-V curve down without changes in the curve shape. Specifically, the curve moved toward the positive direction of the current axis, with the current density exhibiting a significant increase at different membrane potentials (particularly at 70 mV).

Figure 2. I-V curve recordings of Ito (data from double determinations in n = 3 rats, representing a total of n = 6 measurements). (A) I-V traces recorded before and after the administration of ALO. (B) Effects of ALO on Ito current density under different voltages. Values are presented as mean ± SD. *p < 0.05, **p < 0.01 vs. the control.

Figure 3. Effects of ALO on the activation gated-kinetic characteristics of Ito (data from double determinations in n = 3 rats, representing a total of n = 6 measurements). Values are presented as mean ± SDs (n = 6). *p < 0.05, **p < 0.01 vs. the control.

To investigate the relationship between the inhibitory effect of ALO on Ito and the activation state of voltage-gated potassium channels, we fitted the activation curve based on the relevant data from the I-V curves. This allowed us to assess the impact of ALO on activation kinetics curves. As presented in Figure 3, various concentrations of ALO induced a shift in the activation curve of Ito in a positive direction. Particularly, the administration of 3 and 10 μM ALO in an increase in the V1/2-ac value from 12.58 ± 1.70 mV (pre-administration) to 19.48 ± 1.74 and 37.55 ± 1.67 mV (data from double determinations in n = 3 rats, representing a total of n = 6 measurements; p < 0.01 vs. control), respectively. Furthermore, the slope (κ) values were 16.73 ± 1.76 (pre-administration), 18.79 ± 1.88 (data from double determinations in n = 3 rats, representing a total of n = 6 measurements; p > 0.05 vs. control), and 30.17 ± 1.72 (data from double determinations in n = 3 rats, representing a total of n = 6 measurements; p < 0.01 vs. control). Consequently, ALO slowed the activation of Ito, thus blocking the opening of the potassium channel.

To test the relationship between ALO and the inactivation state in the gating dynamics characteristics, the stimulus protocols were as follows: the condition pulse was gradually depolarized from −120 mV to 30 mV in 10 mV increments for 1,000 ms at a holding potential of −80 mV, and a test pulse was set to 70 mV for 300 ms. The currents before and after ALO administration were induced by the double-pulse stimulation (Figure 4A). The steady-state inactivation curve was fitted using the Boltzmann equation I/Imax=1/1+⁡expV−V1/2/K ; Eq. 1, where V1/2 indicates the potential corresponding to the half-maximal inactivation point and κ represents the slope factor. As presented in Figure 4B, 10 μM ALO significantly shifted the inactivation curve of Ito to the left in the direction of hyperpolarization, whereas 3 μM ALO resulted in no obvious changes compared to the control group. The V1/2-in values before and after the administration of ALO were changed from −46.62 ± 1.94 mV (pre-administration) to −48.74 ± 1.09 mV (data from double determinations in n = 3 rats, representing a total of n = 6 measurements; p > 0.05 vs. control) and −65.56 ± 1.02 mV (data from double determinations in n = 3 rats, representing a total of n = 6 measurements; p < 0.01 vs. control), respectively. Moreover, the κ values were 15.86 ± 0.87 (pre-administration), 15.90 ± 1.07 (data from double determinations in n = 3 rats, representing a total of n = 6 measurements; p > 0.05 vs. control), and 29.83 ± 1.97 (data from double determinations in n = 3 rats, representing a total of n = 6 measurements; p < 0.01 vs. control), respectively. These results reveal that the steady-state inactivation process was only affected by 10 μM ALO.

Figure 4. Effects of ALO before and after administration on the inactivation curve (data from double determinations in n = 3 rats, representing a total of n = 6 measurements). (A) Original traces of Ito recorded in the presence or absence of ALO. (B) Steady-state inactivation dynamic characteristics for control and after 3 and 10 μM ALO treatments. Data are provided as the mean ± SDs (n = 6). *p < 0.05, *p < 0.01 vs. the control.

The steady-state recovery curves after inactivation were acquired via the double pulse voltage protocol as follows: Initially, a holding potential of −80 mV was maintained, followed by a depolarization to 70 mV stimulus for 200 ms. Subsequently, repolarization to 70 mV for 200 ms was conducted, and the interval time between two pulses was gradually increased by 50 ms for a total of 20 pulses. The original current of the curve before and after ALO administration was documented (Figure 5A), and it is provided in Figure 5B. The steady-state recovery curves after inactivation of Ito were fitted by the one-phase association equation described as I/Imax=1 –⁡exp−t/τ Eq. 2, where t represents the time interval between two pulses and τ is the time constant of reactivation after inactivation. Thereafter, the τ value was changed from 43.51 ± 3.06 ms under control conditions to 56.73 ± 3.03 ms in response to 3 μM ALO (n = 6; p < 0.05 vs. control) and 65.93 ± 3.55 ms in response to 10 μM ALO (n = 6; p < 0.01 vs. control). The results indicated that 3 and 10 μM ALO significantly inhibited Ito by affecting the recovery kinetic characteristics after inactivation and prolonging the recovery time after inactivation.

Figure 5. Effects of ALO on the Ito recovery curve after inactivation in atrial myocytes (data from double determinations in n = 3 rats, representing a total of n = 6 measurements). (A) Original traces in control and in response to 3 or 10 μM ALO. (B) Kinetic characteristics of the recovery curve after inactivation were analyzed in both control conditions and in response to ALO (3 or 10 μM). Values are presented as mean ± SD. *p < 0.05, **p < 0.01 vs. the control.

The representative ECGs in rats are presented in Figure 6. The control group exhibited a normal ECG. Varying RR intervals, the appearance of f waves, and the disappearance of p waves are considered indicators of AF onset, while the disappearance of f waves and the appearance of p waves are considered indicators of AF termination. AF models were successfully established in other groups. The induction rate of AF in model group is greater than 80%. Compared to the model group, pretreatment with amiodarone and ALO prolonged the induction time of AF and reduced the duration of AF in the animal models, as shown in Table 2.

Figure 6. Representative ECG recordings, from a normal rat (A), and of an AF rat (B).

Table 2. Induction and duration time of AF among rats in each group.

XP docking results should be interpreted based on the XP Gscore. Typically, a value below −6 is considered indicative of stable binding performance between the ligand and the protein. MM-GBSA analysis results should be referred to as MM-GBSA dG Bind, and when this value is below −30 kcal/mol, it suggests low binding free energy and indicates a stable binding between the ligand and the protein. The docking score of ALO with KCND2 is −3.990, and the MM-GBSA dG Bind result is −30.68 kcal/mol, thus indicating stable binding. In contrast, the docking scores of ALO with KCND3 and KCNIP4 are −2.106 and −5.339, with MM-GBSA dG Bind results of −10.67 and −7.2 kcal/mol, respectively. The higher binding free energy suggests fewer stable interactions of ALO with these two proteins. Additionally, the docking score of amiodarone with KCND2 is −1.75, and the MM-GBSA result is −35.26 kcal/mol. Despite the low binding free energy, the high docking score suggests a low likelihood of binding between amiodarone and KCND2, but the stability after binding may still be substantial. The docking scores of amiodarone with KCND3 and KCNIP4 are −5.363 and −3.004, respectively, with MM-GBSA results of −23.67 and −27.66 kcal/mol. Both the binding free energy and docking scores are relatively low, thus indicating a stable binding of amiodarone with these two proteins. The results of the molecular docking assessments are presented in Table 3 and Figure 7.

Table 3. Molecular docking results.

Figure 7. Molecular docking between ALO and the three proteins (KCND2, KCND3, and KCNIP4) based on crystal structures: (A). The ligand forms a salt bridge with the residue ASP64; (B). The ligand forms a π-cation bond with the residue HIE104; (C). KCNIP4. Molecular docking between amiodarone and the three proteins (KCND2, KCND3, and KCNIP4) based on crystal structures: (D). The ligand forms a π-π bond with the residue TYR62; (E). The ligand forms two π-π bonds with the residue HIE104 and a halogen bond with the residue ARG92; (F). The ligand forms a π-cation bond with the residue ARG154 and a hydrogen bond with a salt bridge with the GLU86 residue.

AF often leads to high disability and mortality rates, as well as complications such as stroke and heart failure, imposing significant economic burdens on society (Varró et al., 2021). It is currently a serious cardiovascular disease that seriously endangers public health. Kv channels, crucial for cardiac electrical activity, primarily influence the repolarization process of AP and contribute significantly to excitation-contraction coupling and arrhythmias (Zhang et al., 2006; Amin et al., 2010). Inhibiting Ito can prolong APD, reduce ventricular prematureness, halt phase 2 re-entry, and ultimately prevent the occurrence of ventricular tachycardia and fibrillation (Marquez et al., 2007). Moreover, alterations in the current amplitude and dynamic properties of Ito indirectly influence the activation and inactivation of other ion channels, consequently impacting the AP shape, APD, and ERP. Therefore, Ito is an important current that controls the AP in myocardial cells. Repolarization is governed by a delicate balance of various inward and outward transmembrane ionic currents, along with electrogenic pump mechanisms. Repolarization reserve plays a crucial role in elucidating the pathogenesis of arrhythmias stemming from repolarization abnormalities and drug-induced proarrhythmic adverse effects (Varró and Baczkó, 2011; Virág et al., 2011). Understanding the impact of Ito inhibition on patients with impaired repolarization reserve is essential for elucidating the mechanisms underlying arrhythmias and guiding potential therapeutic interventions. In a study, inhibiting Ito in cases of impaired repolarization reserve may lead to excessive prolongation of repolarization, resulting in the formation of early afterdepolarizations, thereby increasing the risk of arrhythmias (Varró and Baczkó, 2011). An increase in Ito is the mechanism that causes Brugada syndrome and early repolarization syndrome. Excessive inhibition or an increase in Ito may induce abnormal changes in the channel, ultimately resulting in cardiovascular disease. In our experiment, we utilized 3 and 10 μM ALO, without employing higher concentrations. In our current study, 10 µM of ALO inhibited Ito, suggesting its ability to block transient outward potassium channels. However, as the concentration increased to 30 and 100 μM, we noted an increasing trend in Ito (pA/pF). This result may stem from the complex mechanisms of action of ALO on ion channels. At higher doses, ALO may interact with other cellular components or pathways that counteract its effects on Ito, or it may produce other effects on cellular electrophysiology. This change may be attributed to the concentration-dependent effects of ALO, where its selectivity or affinity for ion channels may vary at different concentrations. Additionally, another possibility is that at higher concentrations, ALO may saturate its target binding sites, leading to a plateau effect on Ito inhibition. The combined effects of these factors may result in the observed increasing trend in Ito at concentrations of 30 and 100 µM. Further research is needed to elucidate the detailed molecular mechanisms.

Our data indicate that 3 and 10 μM ALO treatments inhibited the current density of Ito. The gated kinetics analyses revealed that ALO decreased the Ito current density, possibly by decelerating the steady-state activation process of the channel and shifting the half-activation voltage to a positive value. This indicates a reduction in the opening of the channel under the same depolarization voltage stimulation. Additionally, ALO accelerated the inactivation of Ito, shifted the inactivation curve to the left, and extended the recovery time after steady-state inactivation. This caused the recovery curve to move to the right, and this slowed down the recovery process from the inactive state. Hence, the antiarrhythmic mechanism of ALO might be elucidated by its inhibition of Ito in a concentration-dependent manner, which impacts the processes of steady-state activation, inactivation, and recovery after inactivation.

Acetylcholine exposure increases the opening of the acetylcholine-sensitive potassium channel (IK-Ach) in the atrium, leading to a notable enhancement in the potassium outflow current intensity. This results in the shortening of atrial repolarization time and action potential duration (APD), subsequently shortening the effective inactivity period, and contributing to fold formation, and further promoting AF (Moss et al., 2018). Moreover, acetylcholine can diminish sinoatrial node autoregulation by activating M receptors, resulting in a relative increase in atrial potential pacing point autoregulation, thereby contributing to folding and AF formation. Calcium chloride increases inward Ca2+ flow during the phase 2 plateau, thus leading to shortened ERP and APD and facilitating easier maintenance of AF (Li et al., 2018; Fan et al., 2023). The administration of ALO prolonged the induction time of AF and shortened the duration of AF in rats. The results for the in vivo ECG parameters revealed that ALO may prevent acetylcholine-induced AF in rats. The principle of clinical drug administration is to administer the drug as sparingly as possible to achieve therapeutic effects, ensuring optimal dosage, maximizing its protective effects, and minimizing side effects. The blood concentration of a drug serves as a measure of its concentration in the body and is directly linked to the efficacy and toxicity of the drug. A LC-MS/MS method was effectively developed and validated to quantitatively measure ALO in rat plasma with speed and sensitivity, demonstrating its suitability for investigating ALO pharmacokinetics. The method unveiled a relatively high oral bioavailability of 44.87% following both oral and intravenous administrations (Huang et al., 2021).

Although the mechanism of AF induced by calcium chloride and acetylcholine is clearly understood, additional arrhythmias and abnormal electrocardiographic phenomena have been observed in AF animal models. Further studies are required to determine if calcium chloride and acetylcholine play a role in these processes (Bayer et al., 2019). In addition to atria, calcium chloride and acetylcholine can act on the ventricular muscle, particularly calcium chloride (Murray et al., 2022). The transient atrioventricular block after administration that lasts <1 min is associated with an atrioventricular conduction disturbance caused by acetylcholine that disappears naturally after acetylcholine is hemodiluted and metabolized. Overloaded intracellular calcium leads to myocardial cell damage resulting in conduction disturbances in the ventricular myocardium, delayed post-depolarization leading to increased autoregulation at ectopic rhythm points, and increased Ca2+ inward flow that leads to shortened ERP and APD and forms the basis for all types of ventricular tachycardia (Wleklinski et al., 2020). Myocardial conduction disturbances results in heterogeneous myocardial repolarization and increased dispersion of myocardial repolarization across the wall, which may be associated with QRS-T-wave electrical alternations. Polymorphic ventricular premature beats can occur due to increased autoregulation and shortened effective inactivity at ectopic rhythm points. When ventricular premature beats occur late, the atria cannot be excited by retrograde transmission, but can be excited by the sinoatrial node. As a result, normal P waves may be observed earlier in the ventricle.

Kv4.2 (encoded by KCND2) is a predominant transient outward potassium channel. In the molecular docking stimulation, ALO binds to the surface of the active pocket of the KCND2 protein, forming hydrophobic interactions with residues ILE128, PRO126, ILE125, and LEU124 of the Kcnd2 protein. Additionally, this ligand formed a salt bridge with residue ASP64. ALO binds to the active pocket surfaces of both KCND3 and KCNIP4 proteins, but the interactions are relatively unstable. The results of molecular docking experiments revealed that ALO could stably bind to the KCND2 protein. These results provide a rational explanation for how ALO affects cardiomyocyte Ito gating kinetics.

However, it is important to acknowledge the limitations of our study. Cardiac potassium channels are classified into transient outward, delayed rectifier outward, and inward rectifier currents. Our investigation primarily focused on the inhibitory effects of ALO on Ito in rat ventricular myocytes and did not explore its potential effects on other potassium ion channels or cardiac electrophysiological parameters. Future comprehensive studies, including both basic research and clinical trials, are needed to provide more robust evidence.

In conclusion, ALO regulates Ito by reducing the current densities of Ito and affecting the channel gating kinetic characteristics to stabilize the cardiac repolarization process and reduce the risk of arrhythmias.

We thank the Center of Pharmaceutical Technology of Tsinghua University for the support of Schrodinger software and molecular docking. We would like to thank Editage (www.editage.cn) for English language editing.

Bayer, J. D., Boukens, B. J., Krul, S. P. J., Roney, C. H., Driessen, A. H. G., Berger, W. R., et al. (2019). Acetylcholine delays atrial activation to facilitate atrial fibrillation. Front. Physiol. 10, 1105. doi:10.3389/fphys.2019.01105

PubMed Abstract | CrossRef Full Text | Google Scholar

Brundel, B., Ai, X., Hills, M. T., Kuipers, M. F., Lip, G. Y. H., and de Groot, N. M. S. (2022). Atrial fibrillation. Nat. Rev. Dis. Prim. 8 (1), 21. doi:10.1038/s41572-022-00347-9

PubMed Abstract | CrossRef Full Text | Google Scholar

Drum, B. M., Yuan, C., Li, L., Liu, Q., Wordeman, L., and Santana, L. F. (2016). Oxidative stress decreases microtubule growth and stability in ventricular myocytes. J. Mol. Cell Cardiol. 93, 32–43. doi:10.1016/j.yjmcc.2016.02.012

PubMed Abstract | CrossRef Full Text | Google Scholar

Fan, X., Feng, K., Liu, Y., Yang, L., Zhao, Y., Tian, L., et al. (2023). miR-135a regulates atrial fibrillation by targeting Smad3. Cardiovasc Ther. 2023, 8811996. doi:10.1155/2023/8811996

PubMed Abstract | CrossRef Full Text | Google Scholar

Guinamard, R., Hof, T., and Salle, L. (2014). Current recordings at the single channel level in adult mammalian isolated cardiomyocytes. Methods Mol. Biol. 1183, 291–307. doi:10.1007/978-1-4939-1096-0_19

PubMed Abstract | CrossRef Full Text | Google Scholar

Huang, S., Zhang, Y., Zhang, Y., Liu, J., Liu, Z., and Wang, X. (2021). Establishment of LC-MS/MS method for determination of aloperine in rat plasma and its application in preclinical pharmacokinetics. J. Chromatogr. B 1173, 122671. doi:10.1016/j.jchromb.2021.122671

CrossRef Full Text | Google Scholar

Lei, M., Wu, L., Terrar, D. A., and Huang, C. L. H. (2018). Modernized classification of cardiac antiarrhythmic drugs. Circulation 138 (17), 1879–1896. doi:10.1161/CIRCULATIONAHA.118.035455

PubMed Abstract | CrossRef Full Text | Google Scholar

Li, M.-t., Du, Y. Y., Zhong, F., Wang, J. R., Gu, Y. W., Zhang, Y., et al. (2021). Inhibitory effects of aloperine on voltage-gated Na+ channels in rat ventricular myocytes. Naunyn-Schmiedeberg's Archives Pharmacol. 394 (7), 1579–1588. doi:10.1007/s00210-021-02076-4

CrossRef Full Text | Google Scholar

Li, W., Li, Y., Zhao, Y., and Ren, L. (2020b). The protective effects of aloperine against ox-LDL-induced endothelial dysfunction and inflammation in HUVECs. Artif. Cells Nanomed Biotechnol. 48 (1), 107–115. doi:10.1080/21691401.2019.1699816

PubMed Abstract | CrossRef Full Text | Google Scholar

Li, Y., Song, B., and Xu, C. (2018). Effects of Guanfu total base on Bcl-2 and Bax expression and correlation with atrial fibrillation. Hell. J. Cardiol. 59 (5), 274–278. doi:10.1016/j.hjc.2018.02.009

PubMed Abstract | CrossRef Full Text | Google Scholar

Li, Y., Wang, G., Liu, J., and Ouyang, L. (2020a). Quinolizidine alkaloids derivatives from Sophora alopecuroides Linn: bioactivities, structure-activity relationships and preliminary molecular mechanisms. Eur. J. Med. Chem. 188, 111972. doi:10.1016/j.ejmech.2019.111972

PubMed Abstract | CrossRef Full Text | Google Scholar

Lv, X. Q., Zou, L. L., Tan, J. L., Li, H., Li, J. R., Liu, N. N., et al. (2020). Aloperine inhibits hepatitis C virus entry into cells by disturbing internalisation from endocytosis to the membrane fusion process. Eur. J. Pharmacol. 883, 173323. doi:10.1016/j.ejphar.2020.173323

PubMed Abstract | CrossRef Full Text | Google Scholar

Manville, R. W., van der Horst, J., Redford, K. E., Katz, B. B., Jepps, T. A., and Abbott, G. W. (2019). KCNQ5 activation is a unifying molecular mechanism shared by genetically and culturally diverse botanical hypotensive folk medicines. Proc. Natl. Acad. Sci. U. S. A. 116 (42), 21236–21245. doi:10.1073/pnas.1907511116

PubMed Abstract | CrossRef Full Text | Google Scholar

Mao, Q., Guo, F., Liang, X., Wu, Y., and Lu, Y. (2019). Aloperine activates the PI3K/akt pathway and protects against coronary microembolisation-induced myocardial injury in rats. Pharmacology 104 (1-2), 90–97. doi:10.1159/000500761

PubMed Abstract | CrossRef Full Text | Google Scholar